AbbVie Announces Upadacitinib (RINVOQ) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3
Portfolio Pulse from Benzinga Newsdesk
AbbVie announced that its Phase 2b study evaluating upadacitinib in adults with non-segmental vitiligo met the primary endpoint. The company is advancing its clinical program of upadacitinib in vitiligo to Phase 3. No new safety signals were identified beyond the known safety profile for upadacitinib.
October 12, 2023 | 9:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's successful Phase 2b study of upadacitinib and its advancement to Phase 3 could potentially boost the company's stock in the short term.
Positive clinical trial results often lead to increased investor confidence, which can drive up the stock price. The advancement to Phase 3 indicates that the company is making progress in its drug development, which is also a positive signal to investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100